The level of plasma homocysteine in patients with non-alcoholic fatty liver disease in combination with type 2 diabetes

Authors

  • V. F. Orlovskiy
  • N. G. Kuchma
  • A. V. Orlovskiy
  • N. O. Murenets

DOI:

https://doi.org/10.14739/2310-1210.2015.3.44489

Keywords:

Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, Homocysteine

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the major causes of chronic diseases of the hepatobiliary zone.

Aim. In order to explore new pathogenetic factors of NAFLD examined the level of plasma homocysteine in 110 patients.

Methods and results. Patients were divided into two groups - the isolated NAFLD and in combination with Diabetes mellitus type 2. Found a significant increase in homocysteine level in all patients with NAFLD compared with the control group. High homocysteine concentration was in patients with comorbidity. There was positive correlation between levels of homocysteine and lipid components and cytolytic syndrome in all patients.

Conclusion. The data obtained allow us to consider homocysteine as one of the factors in the pathological changes development in the liver.

References

Smith, B. W., & Adams, L. A. (2011). Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and. Nature Reviews Endocrinology, 7(8), 456–465. doi: 10.1038/nrendo.2011.72.

Kantartzis, K. Gastaldelli, A., Magkos, F., & Lavoie, J. (2012). Diabetes and Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research, 2012, 1–23.

Babak, O. Ya. (2010). Prichiny i metabolicheskie posledstviya nealkogol'noj zhirovoj bolezni pecheni [Causes and metabolic consequences of non-alcoholic fatty liver disease]. Suchasna gastroenterologiia, 4(54), 8–16. [in Ukrainian].

Tacer, F. К., & Rozman, D. (2011). Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation. Journal of Lipids, 2011, 1–14. doi: 10.1155/2011/783976.

Leach, N., Dronca, E., Vesa, S., Sampelean, D., Craciun, E., Lupsor, M., et al. (2014). Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. European Journal of Internal Medicine, 25(8), 762–767. doi: 10.1016/j.ejim.2014.09.007.

Zvyaginceva, T. D., Chernobaj, A. I., Glushchenko, S. V. (2014). Rol' ademetionina v razvitii i progressirovanii khronicheskikh zabolevanij pecheni [Ademetionine role in the development and progression of chronic liver disease]. Ukrainskyi medychnyi chasopys, 3(101), 56–59. [in Ukrainian].

Adinolfi, L. E., Zampino, R., Restivo, L., Lonardo, A., Guerrera, B., Marrone, A., et al. (2014). Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. World J Gastroenterol, V20(13), 3410–3417. doi: 10.3748/wjg.v20.i13.3410.

Zbidi, Н, Redondo, P. C., Lopez, J., Bartegi, A., Salido, G., & Rosado, J. A. (2010). Homocysteine induces caspase activation by endoplasmic reticulum stress in platelets from type 2 diabetics and healthy donors. Thrombosis and Haemostasis, 103(5), 1022–1032. doi: 10.1160/TH09-08-0552.

Younossi, Z. M., Gramlich, T., Matteoni, C. A., Boparai, N., & McCullough, A. (2004). Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol, 2(3), 262–265.

Skybchyk, V. A., & Solomenchuk, T. M. (2005). Diabetychna dyslipidemiia: kryterii diahnostyky i suchasna stratehiia likuvannia [Diabetic dyslipidemia: diagnostic criteria and current treatment strategy]. Ukrainskyi medychnyi chasopys, 1(45), 26–33. [in Ukrainian].

How to Cite

1.
Orlovskiy VF, Kuchma NG, Orlovskiy AV, Murenets NO. The level of plasma homocysteine in patients with non-alcoholic fatty liver disease in combination with type 2 diabetes. Zaporozhye Medical Journal [Internet]. 2015Jun.15 [cited 2024Jun.18];17(3). Available from: http://zmj.zsmu.edu.ua/article/view/44489

Issue

Section

Original research